| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Are we shifting attrition downstream in the HIV cascade?
|
Fox, Matthew P
|
|
2016
|
3 |
12 |
p. e554-e555
nvt p.
|
artikel
|
| 2 |
Committing to disability inclusion to end AIDS by 2030
|
Hanass-Hancock, Jill
|
|
2016
|
3 |
12 |
p. e556-e557
nvt p.
|
artikel
|
| 3 |
Evaluating strategies to improve HIV care outcomes in Kenya: a modelling study
|
Olney, Jack J
|
|
2016
|
3 |
12 |
p. e592-e600
nvt p.
|
artikel
|
| 4 |
GBD 2015 and HIV estimates from the Optima model
|
Kelly, Sherrie L
|
|
2016
|
3 |
12 |
p. e558-
1 p.
|
artikel
|
| 5 |
GBD 2015 and HIV estimates from the Optima model – Authors' reply
|
Wang, Haidong
|
|
2016
|
3 |
12 |
p. e558-e559
nvt p.
|
artikel
|
| 6 |
Improved labelling of antiretrovirals for paediatric use
|
Burger, David M
|
|
2016
|
3 |
12 |
p. e550-e551
nvt p.
|
artikel
|
| 7 |
Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment
|
McGowan, Ian
|
|
2016
|
3 |
12 |
p. e569-e578
nvt p.
|
artikel
|
| 8 |
Next-generation sequencing and HIV drug resistance surveillance
|
Hamers, Raph L
|
|
2016
|
3 |
12 |
p. e553-e554
nvt p.
|
artikel
|
| 9 |
Obstacles to prescribers' initiation early antiretroviral therapy: a barrier to achieving 90-90-90 goals
|
Medland, Nicholas A
|
|
2016
|
3 |
12 |
p. e559-e560
nvt p.
|
artikel
|
| 10 |
Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey
|
Ávila-Ríos, Santiago
|
|
2016
|
3 |
12 |
p. e579-e591
nvt p.
|
artikel
|
| 11 |
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial
|
Gaur, Aditya H
|
|
2016
|
3 |
12 |
p. e561-e568
nvt p.
|
artikel
|
| 12 |
The allure of a simple story
|
The Lancet HIV,
|
|
2016
|
3 |
12 |
p. e549-
1 p.
|
artikel
|
| 13 |
When is a PrEP candidate ready for phase 3?
|
Hendrix, Craig
|
|
2016
|
3 |
12 |
p. e551-e553
nvt p.
|
artikel
|
Tijdschrift beschrijving